Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses

Molecular Therapy

Volumn 24, Issue 1, 2016, Pages 146-155

  Katakowski, Joseph A ^a   Mukherjee, Gayatri ^a   Wilner, Samantha E ^a   Maier, Keith E ^a   Harrison, Michael Travis ^b   Di Lorenzo, Teresa P ^a   Levy, Matthew ^a   Palliser, Deborah ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL RECEPTOR; DEC205 PROTEIN; LIPID NANOPARTICLE; NANOPARTICLE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CD86 PROTEIN, MOUSE; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; ENCAPSULATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; IMMUNOREGULATION; LIVER; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; ANIMAL; CHEMISTRY; GENE EXPRESSION REGULATION; IMMUNOLOGY; INJECTION; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; DENDRITIC CELLS; GENE EXPRESSION REGULATION; INJECTIONS; LIPIDS; LIVER; MICE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; RNA, SMALL INTERFERING;

EID: 84957844235     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.175     Document Type: Article

References (53)

1. Davidson, BL and McCray, PB Jr (2011). Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340
2. Schlitzer, A and Ginhoux, F (2014). Organization of the mouse and human DC network. Curr Opin Immunol 26: 90-99
3. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN., et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114
4. Frank-Kamenetsky, M, Grefhorst, A, Anderson, NN, Racie, TS, Bramlage, B, Akinc, A., et al. (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105: 11915-11920
5. Fitzgerald, K, Frank-Kamenetsky, M, Shulga-Morskaya, S, Liebow, A, Bettencourt, BR, Sutherland, JE., et al. (2014). Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383: 60-68
6. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN., et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18: 1357-1364
7. Semple, SC, Akinc, A, Chen, J, Sandhu, AP, Mui, BL, Cho, CK., et al. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28: 172-176
8. Barros, SA and Gollob, JA (2012). Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev 64: 1730-1737
9. Basha, G, Novobrantseva, TI, Rosin, N, Tam, YY, Hafez, IM, Wong, MK., et al. (2011). Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther 19: 2186-2200
10. Novobrantseva, TI, Borodovsky, A, Wong, J, Klebanov, B, Zafari, M, Yucius, K., et al. (2012). Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. Mol Ther Nucleic Acids 1: e4
11. Yan, X, Kuipers, F, Havekes, LM, Havinga, R, Dontje, B, Poelstra, K., et al. (2005). The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun 328: 57-62
12. Wilner, SE, Wengerter, B, Maier, K, De Lourdes Borba Magalhãs, M, Del Amo, DS, Pai, S., et al. (2012). An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids 1: e21
13. Liang, C, Guo, B, Wu, H, Shao, N, Li, D, Liu, J., et al. (2015). Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med 21: 288-294
14. Ramishetti, S, Kedmi, R, Goldsmith, M, Leonard, F, Sprague, AG, Godin, B., et al. (2015). Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. ACS Nano 9: 6706-6716
15. Inaba, K, Swiggard, WJ, Inaba, M, Meltzer, J, Mirza, A, Sasagawa, T., et al. (1995). Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes. Cell Immunol 163: 148-156
16. Dudziak, D, Kamphorst, AO, Heidkamp, GF, Buchholz, VR, Trumpfheller, C, Yamazaki, S., et al. (2007). Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111
17. Hawiger, D, Inaba, K, Dorsett, Y, Guo, M, Mahnke, K, Rivera, M., et al. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-779
18. Bonifaz, L, Bonnyay, D, Mahnke, K, Rivera, M, Nussenzweig, MC and Steinman, RM (2002). Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196: 1627-1638
19. Bonifaz, LC, Bonnyay, DP, Charalambous, A, Darguste, DI, Fujii, S, Soares, H., et al. (2004). In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199: 815-824
20. Robbins, M, Judge, A and MacLachlan, I (2009). siRNA and innate immunity. Oligonucleotides 19: 89-102
21. Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W., et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007
22. Mahnke, K, Guo, M, Lee, S, Sepulveda, H, Swain, SL, Nussenzweig, M., et al. (2000). The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 151: 673-684
23. Vremec, D, Zorbas, M, Scollay, R, Saunders, DJ, Ardavin, CF, Wu, L., et al. (1992). The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med 176: 47-58
24. Manoharan, M, Akinc, A, Pandey, RK, Qin, J, Hadwiger, P, John, M., et al. (2011). Unique gene-silencing and structural properties of 2-fluoro-modified siRNAs. Angew Chem Int Ed Engl 50: 2284-2288
25. Cekaite, L, Furset, G, Hovig, E and Sioud, M (2007). Gene expression analysis in blood cells in response to unmodified and 2-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol 365: 90-108
26. Judge, AD, Bola, G, Lee, AC and MacLachlan, I (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-505
27. Morrissey, DV, Blanchard, K, Shaw, L, Jensen, K, Lockridge, JA, Dickinson, B., et al. (2005). Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41: 1349-1356
28. Jayaraman, M, Ansell, SM, Mui, BL, Tam, YK, Chen, J, Du, X., et al. (2012). Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 51: 8529-8533
29. Coelho, T, Adams, D, Silva, A, Lozeron, P, Hawkins, PN, Mant, T., et al. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819-829
30. Zheng, X, Vladau, C, Zhang, X, Suzuki, M, Ichim, TE, Zhang, ZX., et al. (2009). A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 113: 2646-2654
31. Van Dissel, JT, Joosten, SA, Hoff, ST, Soonawala, D, Prins, C, Hokey, DA., et al. (2014). A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 32: 7098-7107
32. Korsholm, KS, Agger, EM, Foged, C, Christensen, D, Dietrich, J, Andersen, CS., et al. (2007). The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121: 216-226
33. Rothdiener, M, Beuttler, J, Messerschmidt, SK and Kontermann, RE (2010). Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods Mol Biol 624: 295-308
34. Park, JW, Hong, K, Kirpotin, DB, Colbern, G, Shalaby, R, Baselga, J., et al. (2002). Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8: 1172-1181
35. Choi, CH, Alabi, CA, Webster, P and Davis, ME (2010). Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 107: 1235-1240
36. Bartlett, DW, Su, H, Hildebrandt, IJ, Weber, WA and Davis, ME (2007). Impact of tumorspecific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104: 15549-15554
37. Heyes, J, Palmer, L, Bremner, K and MacLachlan, I (2005). Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 107: 276-287
38. Barros, SA and Gollob, JA (2012). Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev 64: 1730-1737
39. Kumar, V, Qin, J, Jiang, Y, Duncan, RG, Brigham, B, Fishman, S., et al. (2014). Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy. Mol Ther Nucleic Acids 3: e210
40. Girvin, AM, Dal Canto, MC, Rhee, L, Salomon, B, Sharpe, A, Bluestone, JA., et al. (2000). A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol 164: 136-143
41. Odobasic, D, Leech, MT, Xue, JR and Holdsworth, SR (2008). Distinct in vivo roles of CD80 and CD86 in the effector T-cell responses inducing antigen-induced arthritis. Immunology 124: 503-513
42. Machen, J, Harnaha, J, Lakomy, R, Styche, A, Trucco, M and Giannoukakis, N (2004). Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol 173: 4331-4341
43. Phillips, B, Nylander, K, Harnaha, J, Machen, J, Lakomy, R, Styche, A., et al. (2008). A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 57: 1544-1555
44. Guo, M, Gong, S, Maric, S, Misulovin, Z, Pack, M, Mahnke, K., et al. (2000). A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum Immunol 61: 729-738
45. Zhang, X, Schwartz, JC, Almo, SC and Nathenson, SG (2002). Expression, refolding, purification, molecular characterization, crystallization, and preliminary X-ray analysis of the receptor binding domain of human B7-2. Protein Expr Purif 25: 105-113
46. Garboczi, DN, Ghosh, P, Utz, U, Fan, QR, Biddison, WE and Wiley, DC (1996). Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384: 134-141
47. Jeffs, LB, Palmer, LR, Ambegia, EG, Giesbrecht, C, Ewanick, S and MacLachlan, I (2005). A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 22: 362-372
48. Wincott, F, DiRenzo, A, Shaffer, C, Grimm, S, Tracz, D, Workman, C., et al. (1995). Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res 23: 2677-2684
49. Inaba, K, Inaba, M, Romani, N, Aya, H, Deguchi, M, Ikehara, S., et al. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-1702
50. Inaba, K, Swiggard, WJ, Steinman, RM, Romani, N and Schuler, G (2001). Isolation of dendritic cells. Curr Protoc Immunol Chapter 3: Unit 3.7
51. Fuss, IJ, Kanof, ME, Smith, PD and Zola, H (2009). Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol Chapter 7: Unit7.1
52. Nair, S, Archer, GE and Tedder, TF (2012). Isolation and generation of human dendritic cells. Curr Protoc Immunol Chapter 7: Unit7.32
53. Parish, CR, and Warren, HS (2002). Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Curr Protoc Immunol. John Wiley & Sons, Inc 49: 4.9: 4.9.1-4.9.10